Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10019173HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10019323HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10031044HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10025139HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10020261HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10040464HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS20001928HPVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TCGA Plot Options
Drug Information
GeneADRA1A
DrugBank IDDB06207
Drug NameSilodosin
Target IDBE0000501
UniProt IDP35348
Regulation Typeantagonist
PubMed IDs21114397; 17603160; 24198606
CitationsLepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303.@@Yamada S, Kato Y, Okura T, Kagawa Y, Kawabe K: Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull. 2007 Jul;30(7):1237-41.@@Yamanishi T, Mizuno T, Kamai T, Yoshida K, Sakakibara R, Uchiyama T: Management of benign prostatic hyperplasia with silodosin. Open Access J Urol. 2009 Aug 20;1:1-7. doi: 10.2147/rru.s5004.
GroupsApproved
Direct ClassificationIndolecarboxamides and derivatives
SMILESC[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
Pathways
PharmGKBPA165291889
ChEMBLCHEMBL24778